DIRS.INFO The most relevant business & tech news

☆ Buy these stocks with solid earnings power during the volatility, Wolfe Research says
▼ + stars: | 2024-08-14 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

Second quarter earnings season has delivered robust profits despite the recessionary concerns that have roiled the market in recent days. Now, Wolfe Research recommends a handful of stocks that are positioned to outperform in the back half of the year. Here are some of the stocks that made the Wolfe Research screen: Apple was the only "Magnificent Seven" stock that made Wolfe's screen. Zoetis also appeared on the Wolfe screen. Duke Energy , which also reported quarterly results that beat expectations last week, also made Wolfe's screen.

Persons: Chris Senyek, Wolfe, Apple, Luca Maestri, Kellanova, FactSet, Mars, Snickers –, CNBC's David Faber, Hershey, althought, Zoetis Organizations: Wolfe Research, Apple, LSEG, Pfizer Animal Health, Duke Energy Locations: Chicago, New Jersey, North Carolina

☆ Eli Lilly's blowout quarter should quiet investor concerns about the stock
▼ + stars: | 2024-08-08 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +11 min

Eli Lilly on Thursday reported a home-run quarter fueled by sales of its blockbuster obesity and diabetes drugs, quieting any lingering investor concerns in the stock. Eli Lilly Why we own it: Eli Lilly's best-in-class drugs should enable growth above the industry average for many years to come. The report left little doubt that Eli Lilly's best days are ahead, driven by the growth of GLP-1s. It's really early" for Zepbound, Eli Lilly CEO David Ricks said in a CNBC interview Thursday. But the good news is Eli Lilly's multibillion dollar investments to expand manufacturing capacity are paying off.

Persons: Eli Lilly, Eli Lilly's, Zepbound, Jim Cramer, Lilly, David Ricks, It's, We're, Eli Lilly hasn't, Novo, spooked Lilly, Gordon Brooks, it's, Ricks, Brooks, Verzenio, —, didn't, Jim Cramer's, Jim, George Frey Organizations: Revenue, LSEG, Novo Nordisk, Biogen, Merck, Pfizer, CNBC, Food and Drug Administration, Viking Therapeutics, Novo Nordisk —, FDA, RTP, Bloomberg, Getty Locations: Eisai, U.S, GLP, Roche, it's, Indianapolis, North Carolina, Europe, Germany, Provo , Utah

☆ These high-dividend-yielding stocks could see a rebound as rates decline, BMO says
▼ + stars: | 2024-08-07 | by ( Michelle Fox | ) www.cnbc.com time to read: +4 min

Now could be a good time to start buying stocks with high dividend yields, according to BMO Capital Markets. The highest-paying S & P 500 stocks have significantly underperformed the index over the last year and a half, even with the rebound they've enjoyed in recent months, said chief investment strategist Brian Belski. They are rated outperform by the firm's analysts and fall within the top 25% of S & P 500 stocks by dividend yield. Digital Realty Trust, which pays a 3.28% dividend yield, owns, develops and operates data centers — which are expected to see surging demand thanks to AI . Host Hotel & Resorts, which owns luxury and upper-upscale hotels, has a 4.92% dividend yield and is down 16% so far this year.

Persons: they've, Brian Belski, Belski, AbbVie Organizations: BMO Capital Markets, Federal, Fed, BMO, Pfizer, pharma, AbbVie, Cerevel Therapeutics, American Electric Power, Southern Company, Utilities, Digital Realty Trust, Host Hotels, Resorts Locations: Southern

The first round of Medicare drug price negotiations has come to an end – but we still don't know the final prices that the U.S. government and pharmaceutical companies have agreed on. They all maintain that Medicare drug price negotiations are a long-term threat to the pharmaceutical industry's drug innovation and profits, but the immediate dust has somewhat settled. That's based on executive commentary during the recent quarterly earnings calls of Bristol Myers Squibb and Johnson & Johnson , among other companies. Novartis CEO Vasant Narasimhan said on July 18 that the short-term impact from Medicare drug price negotiations "might be manageable on our first set of drugs." Executives at each of the drugmakers similarly emphasized their opposition to Medicare drug price negotiations on their respective earnings calls.

Persons: Joe Biden, Johnson, Joe Biden's, Christopher Boerner, Bristol Myers, Robert Michael, We've, Michael, Jennifer Taubert, Vasant Narasimhan, Narasimhan, Bristol Myers Squibb's Boerner, Boehringer Ingelheim, Annika Organizations: National Institutes of Health, Medicare, Bristol Myers Squibb, Johnson, Pfizer, J, Novartis, Merck, Novo Nordisk, AstraZeneca Locations: Bethesda , Maryland, U.S, annikakim.constantino@nbcuni.com

☆ Insider Today: Mark Cuban vs. Big Pharma
▼ + stars: | 2024-08-04 | by ( Dan Defrancesco | ) www.businessinsider.com time to read: +5 min

But first: Big Tech reporting for duty. AdvertisementEven before Amazon, Apple, Meta, and Microsoft reported earnings, investors' focus was clear. Meta CEO Mark Zuckerberg didn't shy away from his intention to keep plowing money into AI, but investors didn't mind. Softening demand from shoppers for Amazon led to a miss in reported net sales and a weaker-than-expected sales forecast for the third quarter. Also read:Getty Images; Jenny Chang-Rodriguez/BIMark Cuban's pharma missionIn 2022, Mark Cuban launched a low-cost online pharmacy with the goal of cutting drug prices for consumers.

Persons: —, Jeff Bottari, Rebecca Zisser, Tesla, Mark Zuckerberg, iStock, That's, Gen, Zers, Tyler Le, Tetiana Lazunova, Jenny Chang, Rodriguez, Cuban's, Mark Cuban, somebody's, Emily Durham Organizations: Service, Business, Big Tech, Getty Images, Apple, Meta, Microsoft, Apple Intelligence, Amazon, pharma, Cuban's pharma, Cost, Pfizer, Novo Nordisk Locations: China

☆ Tesla's unique approach to sales is giving it headaches
▼ + stars: | 2024-08-02 | by ( Dan Defrancesco | ) www.businessinsider.com time to read: +6 min

The big storyFor saleGetty Images; Jenny Chang-Rodriguez/BIOne of Tesla's biggest assets is its willingness to try new things, but its unique approach to sales is also what's giving it headaches. AdvertisementA key issue is Tesla's inability to evolve its sales tactics as the EV market rapidly changes . Business Insider's Grace Kay spoke to more than a dozen current and former employees in Tesla's sales division about how the company has tried to kick-start its sales unit . Not unlike its cars, Tesla's sales approach is innovative compared to the rest of the automotive industry. It's a great strategy when the cars sell themselves — which Teslas did for a while — since you don't need to maintain a traditional sales structure.

Persons: —, Jenny Chang, Rodriguez, It's, Elon Musk, Insider's Grace Kay, There's, Teslas, Justin Sullivan, Fintechs, chatbots, Rebecca Zisser, Goldman Sachs, James Knightley, Andy Jassy, Mike Blake, Chelsea Jia Feng, Venu, Dan DeFrancesco, Jordan Parker Erb, Hallam Bullock, Annie Smith, Amanda Yen Organizations: Service, Business, EV, Tech, Citadel, ING Economics, Big Pharma, Pfizer, Novo Nordisk, Department of Labor, Chevron, ExxonMobil Locations: New York, London

☆ Moderna stock falls more than 10% as it slashes guidance on low EU sales, tough U.S. vaccine market
▼ + stars: | 2024-08-01 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +5 min

It's Moderna's second-ever commercially available product after its Covid vaccine, which has seen demand plunge as the world emerges from the pandemic and relies less on protective shots and treatments. He added that "we've been having quite intense discussions with governments across Europe" to get Covid vaccine supply from Moderna. He is referring to the European Union's massive renegotiated Covid vaccine supply contract with Pfizer and its German partner BioNTech . Its shares are up nearly 20% this year on increasing confidence around its pipeline and messenger RNA platform, which is the technology used in its Covid vaccine and RSV shot. Moderna is also developing a stand-alone flu shot, a personalized cancer vaccine with Merck and shots for latent viruses, among other products.

Persons: It's Moderna's, Stephane Bancel, we've, Bancel, BioNTech, Moderna, I'm Organizations: Moderna Inc, Moderna, Pfizer, GSK, LSEG, Wall, Research, Merck Locations: Cambridge , Massachusetts, Europe, U.S, Moderna, Ukraine

☆ We asked Mark Cuban how he's going to disrupt Big Pharma. He said it's pretty straightforward, actually.
▼ + stars: | 2024-08-01 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +5 min

Here's how it works: Cost Plus Drugs, as the name implies, gets drugs directly from manufacturers, cutting out the pharmaceutical middlemen and their extra costs. You pay a 15% markup to Cost Plus Drugs, plus a fixed $5 for labor on each medication and $5 for shipping. How much will a name-brand, 30-day supply of the biggest dose of the "little blue pill" (100mg) cost you? A generic form of the same 30-day supply might start somewhere around $250, but can also exceed $1,000. AdvertisementCost Plus tells consumers that it pays the manufacturer $3 for that same 30-day supply of 100mg generic Viagra tablets.

Persons: —, Cuban, Abraham Gonzalez Fernandez, unbranded, isn't, who've, they've Organizations: Service, Big Pharma, Cuban, Plus, Business, Shark, Dallas Mavericks, Pfizer, Novo Nordisk, US Food and Drug Administration Locations: Texas

☆ Moderna stock tumbles 21% as earnings show people aren't getting as many COVID shots
▼ + stars: | 2024-08-01 | by ( Kelly Cloonan | ) www.businessinsider.com time to read: +2 min

Moderna lowered its annual sales forecast as sales of its COVID-19 vaccine dropped by 37%. The company's vaccine sales struggled especially in Europe, where Pfizer has a deal until 2026. AdvertisementPeople are getting fewer COVID-19 shots, and it's hitting former vaccine heavyweight Moderna, new earnings show. The company's second quarter revenue dropped to $241 million, compared to $344 million a year ago, as sales of its COVID-19 vaccine dropped 37% year-over-year. Moderna also lowered its sales forecast for the year to between $3 billion and $3.5 billion, down from its previous forecast of around $4 billion.

Persons: —, it's, Stephane Bancel Organizations: Moderna, Pfizer, Service Locations: Europe, Moderna, Covid

☆ Wall Street says buy stocks that pay dividends with $6 trillion of cash ready to be deployed
▼ + stars: | 2024-07-31 | by ( Matthew Fox | ) www.businessinsider.com time to read: +3 min

Dividend stocks are set to surge as investors deploy $6 trillion from money-market funds, Bank of America says. Investors could be looking to invest their cash as the Fed gets ready to cut interest rates in September. AdvertisementSome of the highest-yielding S&P 500 companies include Walgreens Boot Alliance, Altria, Verizon, Ford, and AT&T. And while the S&P 500 as a whole offers a dividend yield of about 1.25%, there are nearly 300 S&P 500 stocks that offer a higher yield. AdvertisementSome of the high-paying dividend stocks recommended by Belski include Abbvie, Chevron, Duke Energy, Gilead Sciences, and Pfizer.

Persons: —, Savita Subramanian, Subramanian, BMO's Brian Belski, Belski Organizations: Bank of America, Fed, BMO, Gilead Sciences, Service, Treasury, Walgreens Boot Alliance, Altria, Verizon, Ford, Belski, Duke Energy, Pfizer Locations: Chevron, Gilead, Abbvie

☆ Tuesday's rapid fire: Merck, Pfizer, PayPal, Howmet, SoFi
▼ + stars: | 2024-07-30 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailTuesday's rapid fire: Merck, Pfizer, PayPal, Howmet, SoFiJim Cramer looks at five stock outside the CNBC Investing Club portfolio.

Persons: SoFi Jim Cramer Organizations: Merck, Pfizer, PayPal, CNBC, Club

☆ Stocks making the biggest moves premarket: CrowdStrike, Merck, PayPal, JetBlue and more
▼ + stars: | 2024-07-30 | by ( Brian Evans | ) www.cnbc.com time to read: +6 min

Revenue of $695 million was also higher than the $686 million expected. Adjusted earnings of 5 cents per share topped the loss of 2 cents per share forecasted by analysts polled by FactSet. Additionally, Howmet increased its quarterly dividend to 8 cents per share from 5 cents per share, to be payable Aug. 26. JetBlue — Shares jumped 4% after the airline said adjusted earnings per share was 8 cents for the second quarter. Analysts expected a profit of $2.80 per share on revenue of $1.18 billion, according to StreetAccount.

Persons: Woodward, FactSet, LSEG, Archer, Gamble —, Leidos, StreetAccount, — CNBC's Michelle Fox, Hakyung Kim, Lisa Kailai Han, Alex Harring, Jesse Pound, Fred Imbert, John Melloy Organizations: CNBC, Delta Airlines, Microsoft, FactSet, Inc, —, Technology, Merck —, pharma, Semiconductor, Bank of America, Pfizer —, Pfizer, Varonis Systems, Howmet Aerospace, Corning, LSEG, Daniels, Midland, JetBlue —, Revenue, PayPal —, PayPal, Procter, Gamble, U.S . Pentagon Locations: FactSet .

☆ Pfizer's weight loss pill may enter regulatory studies next year, says CEO Albert Bourla
▼ + stars: | 2024-07-30 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPfizer's weight loss pill may enter regulatory studies next year, says CEO Albert BourlaCNBC's Angelica Peebles interviews Pfizer's CEO Albert Bourla to discuss the company's earnings, expectations for its new weight loss drug, and more.

Persons: Albert Bourla CNBC's Angelica Peebles, Albert Bourla

☆ Jim Cramer: Merck is a buy after the drugmaker's post-earnings dip — here's why
▼ + stars: | 2024-07-30 | by ( Matthew J. Belvedere | ) www.cnbc.com time to read: +1 min

Merck : The drugmaker reported a better-than-expected quarter. It raised its full-year sales outlook but was still a little short of estimates. Jim Cramer said Tuesday he would take advantage of the dip and buy Merck ahead of the benefit from this drug. Pfizer : Better-than-expected sales and adjusted earnings, as well as a full-year outlook raise, were not enough to keep the stock higher. PayPal : The digital payments company reported a better-than-expected quarter.

Persons: Jim Cramer's, Jim Cramer, Cramer, Alex Chriss, Anthony Noto Organizations: CNBC, Club, Merck, FDA, Pfizer, PayPal, Aerospace

☆ Final Trades: Pfizer, Bristol Meyers, Textron and Oracle
▼ + stars: | 2024-07-30 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFinal Trades: Pfizer, Bristol Meyers, Textron and OracleThe Investment Committee give you their top stocks to watch for the second half.

Persons: Bristol Meyers Organizations: Pfizer, Textron, Oracle The Investment

☆ Pfizer beats earnings estimates, hikes full-year outlook as drugmaker cuts costs
▼ + stars: | 2024-07-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Pfizer on Thursday reported second-quarter revenue and adjusted earnings that blew past expectations and raised its full-year outlook, benefiting from its broad cost-cutting program, better-than-expected sales of its Covid antiviral pill Paxlovid and strong non-Covid product sales. Pfizer now expects to book adjusted earnings of $2.45 to $2.65 per share for the fiscal year, up from its previous guidance of $2.15 to $2.35 per share. Pfizer also hiked its revenue outlook to a range of $59.5 billion to $62.5 billion, up from a previous revenue forecast of between $58.5 billion and $61.5 billion. 60 cents adjusted vs. 46 cents expected. Revenue: $13.28 billion vs. $12.96 billion expected.

Organizations: Pfizer, LSEG, Revenue Locations: U.S, Seagen

☆ Cramer's Lightning Round: Do not sell Constellation Energy
▼ + stars: | 2024-07-29 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

Stock Chart Icon Stock chart icon Illumina's year-to-date stock performance. Stock Chart Icon Stock chart icon Bank of America's year-to-date stock performance. Stock Chart Icon Stock chart icon Constellation Energy's year-to-date stock performance. Stock Chart Icon Stock chart icon Meta's year-to-date stock performance. Stock Chart Icon Stock chart icon Organon's year-to-date stock performance.

Persons: one's, Jim Cramer's Organizations: of America's, Bank of America, Constellation Energy, ICICI, ICICI Bank, Pfizer, Organon Locations: India

☆ Earnings Exchange: P&G, JetBlue, Pfizer
▼ + stars: | 2024-07-29 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEarnings Exchange: P&G, JetBlue, PfizerLee Munson, Portfolio Wealth Advisors president and CEO, joins CNBC's 'The Exchange' to discuss three stocks: Procter & Gamble, JetBlue, and Pfizer.

Persons: Pfizer Lee Munson Organizations: G, JetBlue, Pfizer, Procter, Gamble

☆ Stock futures are flat in overnight trading ahead of key corporate earnings: Live updates
▼ + stars: | 2024-07-29 | by ( Yun Li | ) www.cnbc.com time to read: +2 min

Stock futures were flat in overnight trading Monday as investors awaited key corporate earnings and the beginning of the Federal Reserve's policy meeting. S&P 500 futures and Nasdaq 100 futures both traded 0.1% higher. That compares to a five-year average earnings beat rate of 77%. "Both 2024 and 2025 consensus EPS are holding up, with 2024 EPS tracking a typical non-recessionary year revision trend. "Inflation is trending lower, supporting Federal Reserve rate cuts," said Seema Shah, chief global strategist at Principal Asset Management.

Persons: Savita Subramanian, Jerome Powell, Seema Shah Organizations: New York Stock Exchange, Stock, Dow Jones, Nasdaq, Merck, Pfizer, PayPal, Procter, Gamble, JetBlue, Microsoft, Devices, Bank of, Fed, Asset Management

☆ These drugmakers are catching up to Eli Lilly and Novo Nordisk in weight loss treatments
▼ + stars: | 2024-07-28 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +6 min

With billions at stake, that's pretty much been a guarantee facing the current market leaders, Eli Lilly and Novo Nordisk , from the start. Their updates are likely to be joined by others in the coming months even as today's incumbents develop their own next-generation weight loss treatments. Other analysts have also grown more optimistic about the future of weight loss treatments. Orforglipron, a once-a-day oral GLP-1 drug that Lilly is working on, had shown a 3% weight loss at 4 weeks. The company is also exploring whether the weight loss treatment could be given only once a month.

Persons: Eli Lilly, drugmakers Roche, Lilly, Denmark's, Trung Huynh, Huynh, Rajesh Kumar, Kumar, Novo, Roche, Roche ADRs, Justin Zelin, Zelin, Viking's, HSBC's Kumar, Novo aren't, —, Nick Wells Organizations: Novo Nordisk, Viking Therapeutics, UBS, HSBC Global Research, Carmot Therapeutics, Food and Drug Administration, Viking, European Association for, Diabetes, Pfizer, Amgen, Therapeutics Locations: Swiss, Novo, San Antonio, Spain

☆ 14 earnings, jobs and the Fed are what we're watching in the market this week
▼ + stars: | 2024-07-27 | by ( Zev Fima | ) www.cnbc.com time to read: +12 min

As for Club earnings, we got positive results from life sciences company Danaher and industrial firm Dover. Ford was a major disappointment and its nearly 20% stock drop for the week was the worst performer in the portfolio. In the week ahead, it's going to be another big week of earnings with the four mega-cap names and 10 other Club names set to report. Linde : We're looking for more of the same — steady earnings growth; 6% is the Street estimate. End market commentary will also help us better formulate our view of the economy — and in turn the stock market.

Persons: Russell, Jerome Powell's, Ford, Stanley Black, Decker, We're, we'll, Elliott, we've, We'll, Kraft Heinz, Vita Coco, COCO, Lam, SIRI, WEN, Jim Cramer's, Jim Cramer, Jim, Michael M Organizations: Nasdaq, Dow, Communication, Honeywell, YouTube, Procter & Gamble, Devices, Microsoft, Starbucks, GE Healthcare, DuPont, Meta, Apple, Coterra Energy, Linde, Silo AI, Elliott Management, GE HealthCare, Amazon, Apple Intelligence, U.S, Labor, Fed, Networks, Procter, Gamble, PayPal, Pfizer, BP, JetBlue Airways, Merck, Solar Inc, Caesars Entertainment, Electronic Arts, EA, Nation Entertainment, Boeing, Cruise, Mastercard, Teva Pharmaceutical, Hess Corp, Arm Holdings, Qualcomm, Lam Research, Western, eBay, EBAY, MGM Resorts, MGM, ConocoPhillips, Mobileye, Canada Goose Holdings, Hershey, Toyota, Dominion Energy, Air Products & Chemicals, Southern Company, International, Coterra Energy Intel, Coinbase, Booking Holdings, LIN, Exxon Mobil, Chevron, LyondellBasell Industries, Jim Cramer's Charitable, CNBC, Traders, New York Stock Exchange, Santiago, Getty Locations: Dover, Eaton, Amazon, China, destocking, Corning, New York City

☆ Apple and Microsoft are among the 'Magnificent Seven' stocks set to report next week. Here's what that means
▼ + stars: | 2024-07-26 | by ( Sarah Min | ) www.cnbc.com time to read: +7 min

On Friday, the tech-heavy S & P 500 and Nasdaq Composite ended the week with losses, down 0.8% and 2.1%, respectively. However, the bulk of Magnificent Seven results is set for release in the week ahead. As it is, all seven of the Magnificent Seven companies closed out the week with losses. FOMC meeting, July jobs report Elsewhere, investors will also be reviewing the latest Federal Reserve interest rate decision set for release on Wednesday. Traders will also get insight into the labor market next week, with the release of the July jobs report on Friday.

Persons: Russell, Ryan Grabinski, John Belton, Tesla, Belton, FactSet, Stanley Black, Decker, Lam, Kraft Heinz, Ingersoll Rand Organizations: Nasdaq, Dow Jones Industrial, Microsoft, Facebook, Apple, Nvidia, 2H, 3Q, Gabelli, Traders, Dallas Fed, Semiconductor, Nation Entertainment, Electronic Arts, Starbucks, Match Group, Caesars Entertainment, Corning, Howmet Aerospace, Procter, Gamble, Pfizer, Merck, Co, PayPal, ADP, Civilian Workers, Chicago PMI, MGM Resorts International, Allstate, Lam Research, eBay, Qualcomm, Western, Cruise Line Holdings, Hess, Boeing, Mobile, Marriott International, GE Healthcare Technologies, Generac Holdings, Mastercard, Labor, PMI, Manufacturing, Intel, Holdings, Motorola Solutions, Technology, Air Products, Chemicals, Jobs, Exxon Mobil, Chevron Locations: Chicago, Albemarle, Kellanova, Hershey, Moderna

☆ Final Trades: Freeport-McMoran, Pfizer, Danaher and United Rentals
▼ + stars: | 2024-07-25 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFinal Trades: Freeport-McMoran, Pfizer, Danaher and United RentalsThe Investment Committee give you their top stocks to watch for the second half.

Organizations: Pfizer, Danaher, United Rentals, Investment Locations: Freeport, McMoran

☆ Pfizer's gene therapy for rare genetic bleeding disorder succeeds in late-stage trial
▼ + stars: | 2024-07-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Pfizer on Wednesday said its experimental gene therapy for a rare genetic blood-clotting disorder succeeded in a large late-stage trial, paving the way for a potential approval. Without enough of that protein, the blood cannot clot properly, increasing the risk of spontaneous bleeding and severe bleeding after surgery. Pfizer said its one-time treatment significantly cut the number of annual bleeding episodes in patients with moderately severe to severe hemophilia A after 15 months. If approved, Pfizer's therapy will compete with BioMarin Pharmaceutical 's one-time treatment Roctavian. BioMarin is reportedly considering whether to divest its hemophilia A therapy, which costs $2.9 million.

Persons: Andrew Leavitt, Pfizer Organizations: Pfizer, Sangamo Therapeutics, BioMarin Locations: U.S

☆ Joe Biden is taking Paxlovid, even though doctors know it doesn't really work
▼ + stars: | 2024-07-18 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +4 min

But some experts wonder why you'd even prescribe this drug, which has been shown in study after study to be lackluster, at best. There is maybe one thing Paxlovid can sort of doThe one thing Paxlovid seems to do is prevent a few hospitalizations in very high-risk patients. Related storiesPfizer's big trial of more than 1200 patients, out in April, suggested that maybe taking Paxlovid can prevent a few hospital admissions among the frailest, most vulnerable patients, but it's tough to say. In the control group (not taking Paxlovid) that number was 10. But other research from the UK, out in May, showed absolutely no difference in mortality when comparing hospitalized patients taking Paxlovid to those who weren't on the drug.

Persons: —, Biden, Karine Jean, Pierre, Pfizer that's, Jeremy Faust, Paxlovid, it's, Faust, COVID Organizations: Service, for Disease Control, Business, White House Press, Pfizer, Paxlovid Locations: California , New Mexico, Nevada, China

Search resuls for: "Pfizer"

25 mentions found